EA Pharma Co., Ltd Announces Upcoming Presentation of PhaseⅠ, Once-Daily Dosing Data for EA1080 (NSHO-101), an Oral α4β7 Inhibitor for Inflammatory Bowel Disease

EA Pharma Co., Ltd.

EA Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, Japan; President, Hidenori Yabune; “EA Pharma”) will give Poster presentations of data on EA Pharma’s originated and developed inflammatory bowel disease treatment, EA1080 (NSHO-101), in the 20th congress of the European Crohn’s and Colitis Organisation (ECCO) being held February 19 to 22, 2025, in Berlin, Germany.

Presentation Details

Title: Oral α4β7 integrin antagonist EA1080 (NSHO-101) demonstrates target engagement and α4β7 integrin receptor occupancy following once-daily administration in healthy volunteers
Authors: B G Feagan; Y Yazawa; T Seki; E Watanabe; H Ohishi; H Ueo; C Saito; U Lorch
Session Name: Guided Poster Session
Session Date and Time: Friday, February 21, 12:40-13:40 CET
Location: CityCube Messe Berlin, Poster Exhibition, Hall 2.2
Poster ID: P0815 (Abstract citation ID: jjae190.0989)

EA1080 (NSHO-101) is a novel, oral, selective α4β7 integrin inhibitor being developed for the potential treatment of patients with IBD. α4β7 is a cell surface receptor that helps regulate the migration of immune cells to the intestine and plays a key role in controlling inflammatory responses. It binds to MAdCAM-1, which is expressed on high endothelial venules in the intestine and is upregulated in response to inflammation. By blocking this interaction, EA1080 (NSHO-101) offers the potential to prevent the adhesion and migration of inflammatory leukocytes into the intestine, thereby reducing inflammation and improving symptoms in IBD.

The PhaseⅠ clinical program for EA1080 (NSHO-101) assessed the safety, tolerability, food effects, pharmacokinetic (PK) and pharmacodynamic (PD) of single and multiple ascending doses of EA1080 (NSHO-101) in 184 healthy volunteers. EA1080 (NSHO 101) was generally safe and well tolerated. EA1080 (NSHO-101) is planned to initiate PhaseⅡ clinical development as a potential treatment for ulcerative colitis (UC) in the first half of 2025.

1. 　About EA Pharma 
   EA Pharma Co., Ltd. is a subsidiary of Eisai Co., Ltd. It was established in April 2016 by integration of the gastrointestinal business unit with more than 60 year’s history of the Eisai Group and the gastrointestinal business unit of the Ajinomoto Group having amino acid as its business core. EA Pharma Co., Ltd., is a specialty pharmaceutical company with a full value chain covering R&D, production & logistics and sales & marketing. For further information on EA Pharma Co., Ltd., please visit https://www.eapharma.co.jp/
   
   
2.     About inflammatory bowel disease (IBD)
   Inflammatory bowel disease is a group of diseases that include ulcerative colitis (UC) and Crohn’s disease (CD). In these diseases, ulcers are formed in the intestinal mucosa. The major symptoms of IBD include abdominal pain, diarrhea and bloody stools. In many cases, the “remission” stage where the symptoms improve and the “relapse” stage where the symptoms deteriorate repeat over time, and patients suffer from the decline of QOL. The mechanism of onset is unknown up to the present. In Japan, IBD is one of the “designated intractable disease” by Ministry of Health, Labour and Welfare. The registered patient number amounts to about 220,000 of UC and about 70,000 of CD in Japan in 2019. The number of patients suffering from IBD has a tendency to increase in recent years.¹⁾
   

Source